The present study evaluates the efficacy of CFI-400945 in a panel of patient-derived pancreatic cancer xenografts displaying a range of growth rates, magnitudes of tumor hypoxia and PLK4 mRNA expression. The gene discussed is PLK4; the disease is familial pancreatic carcinoma.